An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.

This study was an extension to study MA21573 [NCT00750880], which was an open label single
arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or
combination therapy with non-biological disease-modifying antirheumatic drugs (DMARDS), in
patients with moderate to severe active rheumatoid arthritis. Patients who completed the 24
week core study, and had at least a moderate European League Against Rheumatism (EULAR)
response, were eligible to enter this long-term extension study, and received tocilizumab 8
mg/kg intravenous (iv) every 4 weeks. The anticipated time on study treatment was 1-2 years,
and the target sample size was > 500 individuals.